Khalid Abd-Elaziz

Khalid Abd-Elaziz (MBBS, MD, PhD candidate) is a specialist physician in clinical pharmacology and joined CTC Netherlands in 2024. Khalid has been principal and co-investigator in 80+ early phase clinical trials and is an all-round clinical pharmacologist with focus on design, execution, supervising, analysing, monitoring and reporting of clinical trials in healthy volunteers and patients. Khalid has especial interest in first-in-human and high risk phase I and phase II studies.

Latest publications

Concern about Tominersen in Patients with Huntington's Disease. Reply. N Engl J Med. 2024 Mar 14;390(11):1059.

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age. Clin Infect Dis. 2024 Aug 5:ciae364.

Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Cancer Chemother Pharmacol. 2024 Aug 21.

Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first-in-human study. Br J Clin Pharmacol., First published: 18 August 2024.

Validation of a method for the determination of Aderamastat (FP-025) in K 2EDTA human plasma by LC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1245, 124244. Advance online publication.

Tominersen in Adults with Manifest Huntington's Disease. N Engl J Med. 2023 Dec 7;389(23):2203-2205.

https://doi.org/10.15761/CRT.1000371

https://doi.org/10.1002/cpdd.1256

Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study. Neurology and therapy, 11(3), 1353-1374.

Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study. In W. Schlee, B. Langguth, T. Kleinjung, S. Vanneste, & D. De Ridder (Eds.), Tinnitus - An Interdisciplinary Approach Towards Individualized Treatment: From Heterogeneity to Personalized Medicine (pp. 423-440). (Progress in brain research; Vol. 260). Elsevier.

Allergen bronchoprovocation test: an important research tool supporting precision medicine. Current Opinion in Pulmonary Medicine, 27(1), 15-22.

Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases. Current Opinion in Pulmonary Medicine, 27(1), 54-60.

First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects. Clinical Drug investigation, 41, 65-76.

Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer. European clinical respiratory journal, 7(1), Article 1809083.

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. Respiratory Research, 21(1), Article 87.

We provide our customers with cost-effective advice, conduct and reporting of clinical trials.